EUVIMEDEUVIMED entdecken
Open Access

Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors

Sneha Rathi iD, Ann C Mladek, Ju-Hee Oh, Sonja Dragojevic, Danielle M Burgenske, Wenjuan Zhang, Surabhi Talele, Wenqiu Zhang, Katrina K Bakken, Brett L Carlson, Margaret A Connors, Lihong He und 3 weitere

The Journal of Pharmacology and Experimental Therapeutics · 2024-11 · 391 (2) · 346-360

DOI: 10.1124/jpet.123.002002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024-11. Verfasst von Sneha Rathi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J…. Hauptthemen laut MEDLINE: Ataxia Telangiectasia Mutated Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is a disease of the whole brain, with infiltrative tumor cells protected by an intact blood-brain barrier (BBB). GBM has a poor prognosis despite aggressive treatment, in part due to the lack of adequate drug permeability at the BBB. Standard of care GBM therapies include radiation and cytotoxic chemotherapy that lead to DNA damage. Subsequent activation of DNA damage response (DDR) pathways can induce resistance. Various DDR inhibitors, targeting the key regulators of these pathways such as ataxia telangiectasia mutated and Rad3-related (ATR), are being explored as radio- and chemosensitizers. Elimusertib, a novel ATR kinase inhibitor, can prevent repair of damaged DNA, increasing efficacy of DNA-damaging cytotoxic therapies. Robust synergy was observed in vitro when elimusertib was combined with the DNA-damaging agent temozolomide; however, we did not observe improvement with this combination in in vivo efficacy studies in GBM orthotopic tumor-bearing mice. This in vitro-in vivo disconnect was explored to understand factors influencing central nervous system (CNS) distribution of elimusertib and reasons for lack of efficacy. We observed that elimusertib is rapidly cleared from systemic circulation in mice and would not maintain adequate exposure in the CNS for efficacious combination therapy with temozolomide. CNS distribution of elimusertib is partially limited by P-glycoprotein efflux at the BBB, and high binding to CNS tissues leads to low levels of pharmacologically active (unbound) drug in the brain. Acknowledging the potential for interspecies differences in pharmacokinetics, these data suggest that clinical translation of elimusertib in combination with temozolomide for treatment of GBM may be limited. SIGNIFICANCE STATEMENT: This study examined the disconnect between the in vitro synergy and in vivo efficacy of elimusertib/temozolomide combination therapy by exploring systemic and central nervous system (CNS) distributional pharmacokinetics. Results indicate that the lack of improvement in in vivo efficacy in glioblastoma (GBM) patient-derived xenograft (PDX) models could be attributed to inadequate exposure of pharmacologically active drug concentrations in the CNS. These observations can guide further exploration of elimusertib for the treatment of GBM or other CNS tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ataxia Telangiectasia Mutated ProteinsAnimalsMiceHumansCell Line, TumorGlioblastomaTemozolomideProtein Kinase InhibitorsCentral Nervous System NeoplasmsTissue DistributionBlood-Brain BarrierFemaleBrain NeoplasmsAntineoplastic AgentsXenograft Model Antitumor AssaysPyrimidines

Substanzen

Ataxia Telangiectasia Mutated ProteinsTemozolomideProtein Kinase InhibitorsAntineoplastic AgentsPyrimidines

Autor:innen und Institutionen

  • Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo…

ORCID-Profile: Sneha Rathi

Förderung

  • NCI NIH HHS

Zitieren

APA

Rathi, S., Mladek, A. C., Oh, J. H., Dragojevic, S., Burgenske, D. M., Zhang, W., Talele, S., Zhang, W., Bakken, K. K., Carlson, B. L., Connors, M. A., He, L., Hu, Z., Sarkaria, J. N., & Elmquist, W. F. (2024). Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors. The Journal of Pharmacology and Experimental Therapeutics, 391(2), 346-360. https://doi.org/10.1124/jpet.123.002002

Vancouver

Rathi S, Mladek AC, Oh JH, Dragojevic S, Burgenske DM, Zhang W, et al. Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors. The Journal of Pharmacology and Experimental Therapeutics. 2024;391(2):346-360. doi:10.1124/jpet.123.002002

BibTeX
@article{Rathi2024,
  author = {Rathi, Sneha and Mladek, Ann C and Oh, Ju-Hee and Dragojevic, Sonja and Burgenske, Danielle M and Zhang, Wenjuan and Talele, Surabhi and Zhang, Wenqiu and Bakken, Katrina K and Carlson, Brett L and Connors, Margaret A and He, Lihong and Hu, Zeng and Sarkaria, Jann N and Elmquist, William F},
  title = {Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2024},
  volume = {391},
  number = {2},
  pages = {346--360},
  doi = {10.1124/jpet.123.002002}
}
Kostenlos starten →